Evidence map›Paper›PMID 28512226›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.

Hirofumi Ohashi, Yoshiki Koizumi, Kento Fukano, Takaji Wakita, Alan S Perelson, Shingo Iwami, Koichi Watashi

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Hirofumi OhashiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Yoshiki KoizumiSchool of Medicine, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa 920-8640, Japan.
Kento FukanoDepartment of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Takaji WakitaDepartment of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Alan S PerelsonTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545.
Shingo IwamiDepartment of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan; siwami@kyushu-u.org kwatashi@nih.go.jp.
Koichi WatashiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; siwami@kyushu-u.org kwatashi@nih.go.jp.

Funding

Collaborative Integration of HCV Molecular Virology and Mathematical ModelingR01AI078881 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PERELSON, ALAN S, UPRICHARD, SUSAN L. · 2011 to 2025
$7.5M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI078881NIH HHS R01 OD011095
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsHepacivirusHepatitis CHepatitis C, ChronicHumansAntiviral Agents

Identifiers

PMID28512226
PMCPMC5468609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.